Oracea

Bucks County Courier Times - The company recorded $13.1 million in sales for Oracea. The oral drug used to treat the skin disease rosacea, launched in July 2006. The drug was “the key driver of the significant sales growth achieved this quarter. Oracea is now the No. 1 oral ... ...

NEWTOWN, Pa.----CollaGenex Pharmaceuticals, Inc. today announced that Nancy C. Broadbent, chief financial officer, will present at the Thomas Weisel Partners Healthcare Conference 2007.

CollaGenex Pharmaceuticals Announces Highly Positive Results of Phase 2 Dose-Finding Trial of Col-118 for the Treatment ... (Business Wire via Yahoo! Finance)
NEWTOWN, Pa.----CollaGenex Pharmaceuticals, Inc. today announced results of a Phase 2 dose-finding study designed to evaluate the safety and efficacy of Col-118 for the treatment of erythema....

Bucks County Courier Times - The company recorded $13.1 million in sales for Oracea. The oral drug used to treat the skin disease rosacea, launched in July 2006. The drug was “the key driver of the significant sales growth achieved this quarter. Oracea is now the No. 1 oral ...

Decision About European Marketing Authorization for Oracea Postponed ...
Phramalive.com - * Committee of the decentralised approval procedure (CMD) refers decision to a central body of the European regulatory authorities (CHMP) * No impact on the overall result for 2007 expected MARTINSRIED/MUNICH, Germany - July 30, 2007. MediGene AG ... ...

NEWTOWN, Pa.----CollaGenex Pharmaceuticals, Inc. today announced results of a Phase 2 dose-finding study designed to evaluate the safety and efficacy of Col-118 for the treatment of erythema.

CollaGenex Pharmaceuticals Reports Financial Results for the Second Quarter and First Half of 2007 (Business Wire via Yahoo! Finance)
NEWTOWN, Pa.----CollaGenex Pharmaceuticals, Inc. today reported financial results for the second quarter and six months ended June 30, 2007.

Ad hoc: MediGene AG: Decision About European Marketing Authorization for Oracea® Postponedto 2008 Börsennachrichten - ... (Stock World)
Martinsried/Munich - July 30, 2007. MediGene AG (Frankfurt, Prime Standard: MDG) has been informed by CollaGenex Pharmaceuticals Inc., that the decision about the European marketing authorization for the drug Oracea® for the treatment of the skin disease rosacea has been postponed.

German Stocks Climb; MAN, DaimlerChrysler, BMW Pace the Advance (Bloomberg.com)
July 31 (Bloomberg) -- Germany's benchmark DAX Index posted the biggest one-day gain in more than two weeks. MAN AG paced the advance after Europe's third-largest truckmaker reported its 16th consecutive profit increase.

Deutsche Boerse, Deutz, Infineon, MAN: German Equity Preview (Bloomberg.com)
July 31 (Bloomberg) -- The following stocks may rise or fall in German markets. Germany's X-DAX Index climbed 0.9 percent to 7529.98. The index provides an estimate of the DAX Index, based on trading in DAX futures after the Xetra electronic market closes....

Oracea® treats the bumps or pimple-like blemishes of ... what makes Oracea unique ... The dosage of Oracea differs from that of doxycycline used to ...

Oracea
Oracea is the first and only oral therapy approved for rosacea patients. Oracea® has been approved by the Food and Drug Administration (FDA) to treat ...

Oracea Information from Drugs.com
Oracea information from Drugs.com, includes Oracea side effects interactions, indications ... Oracea can make birth control pills less effective. ...

Oracea, Doxycycline, side effects, interactions, overdose, dosage
Oracea is a prescription medicine to treat only the pimples or bumps on the face caused by a condition called rosacea. ... Take Oracea with a full glass of ...

Rosacea.org: A site about Rosacea
Home of the National Rosacea Society. A website about the medical condition Rosacea. ... Oracea (Or-RAY-sha) is the first orally administered, systemically delivered ......